NCT05495568View on ClinicalTrials.gov

To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis

PHASE3CompletedINTERVENTIONAL
Enrollment

367

Participants

Timeline

Start Date

November 7, 2022

Primary Completion Date

August 14, 2023

Study Completion Date

February 5, 2024

Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
BIOLOGICAL

CT-P17

CT-P17 40mg will be subcutaneous administered

BIOLOGICAL

EU-approved Humira

subcutaneous administration

Trial Locations (1)

Unknown

CT-P17 3.3 investigational site, Tallinn

Sponsors

Lead Sponsor

Celltrion
All Listed Sponsors
lead

Celltrion

INDUSTRY

NCT05495568 - To Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis | Biotech Hunter | Biotech Hunter